Anlon healthcare Limited has notified stock exchanges about new product development and the positive impact of the recently signed India-European Union trade agreement on its business operations. The company submitted its disclosure to BSE and NSE on January 28, 2026, in compliance with Regulation 30 of SEBI Listing Regulations.

Trade Agreement Impact

The Government of India and the European Union have signed a comprehensive trade agreement designed to enhance trade and investment between the two regions. According to the company's filing, this agreement is expected to have a positive impact on Anlon Healthcare's operations.

European Market Presence

Anlon Healthcare has already established its presence in the European market by exporting one of its key products to Italy and Germany. This existing footprint in European Union countries positions the company to potentially benefit from the enhanced trade relationship established through the new agreement.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Punitkumar Rasadia, Managing Director with DIN 06696258.

The company requested both stock exchanges to take the information on record as part of its ongoing disclosure obligations to keep investors informed about material developments.

Anlon Healthcare has received a disclosure from Neomile Asset Managers Private Limited regarding a significant reduction in shareholding under SEBI regulations. The Mumbai-based asset management firm has sold a substantial portion of its equity stake in the healthcare company through open market transactions.

Share Sale Details

Neomile Asset Managers, along with its associated entities Neomile Growth Fund – Series I and Neomile Corporate Advisory Limited, disposed of 13,07,378 equity shares of Anlon Healthcare. The transaction represents 2.46% of the company's total share capital and was executed through open market sales between November 6, 2025, and January 9, 2026.

Shareholding Changes

The sale has resulted in a notable change in Neomile's ownership structure in Anlon Healthcare. Prior to this transaction, the asset management firm and its associated entities held a combined stake of 7.62% in the company.

Regulatory Compliance

The disclosure was made in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulation, 2011. The notification was simultaneously submitted to both the National Stock Exchange of India Limited (NSE) and BSE Limited, where Anlon Healthcare's shares are listed under the scrip codes AHCL and 544497 respectively.

The disclosure was signed by CA Rashesh Shah, Director of Neomile Asset Managers Private Limited, and submitted on January 9, 2026. The document confirms that Neomile and its associated entities do not belong to the promoter or promoter group of Anlon Healthcare.

Company Information

Anlon Healthcare Limited, incorporated under CIN U24230GJ2013PLC077543, operates from its registered office in Rajkot, Gujarat. The company's shares continue to trade on both major Indian stock exchanges, with the total equity share capital remaining unchanged at 5,31,51,500 shares post-transaction.